BIOVIT Stock Overview
Bio Vitos Pharma AB (publ) opera como empresa de tecnología médica en Suecia y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bio Vitos Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.24 |
| 52 Week High | kr1.25 |
| 52 Week Low | kr0.085 |
| Beta | 1.55 |
| 1 Month Change | 32.96% |
| 3 Month Change | 6.79% |
| 1 Year Change | -18.62% |
| 3 Year Change | -92.74% |
| 5 Year Change | -97.05% |
| Change since IPO | -96.10% |
Recent News & Updates
Shareholder Returns
| BIOVIT | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 12.4% | -0.02% | -0.002% |
| 1Y | -18.6% | -7.7% | 13.9% |
Rentabilidad frente al sector: BIOVIT obtuvo unos resultados inferiores a los del sector Swedish Medical Equipment , que el año pasado arrojó un rendimiento del -3.8%.
Rentabilidad vs. Mercado: BIOVIT obtuvo unos resultados inferiores a los del mercado Swedish, que fue del 4.8% el año pasado.
Price Volatility
| BIOVIT volatility | |
|---|---|
| BIOVIT Average Weekly Movement | 16.0% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Precio estable de las acciones: BIOVITha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: BIOVITha disminuido de 30% a 24% en el último año, pero sigue siendo superior al 75% de los valores de Swedish.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1 | Jesper Birgemo | https://biovitospharma.com |
Bio Vitos Pharma AB (publ) opera como empresa de tecnología médica en Suecia y a escala internacional. La empresa desarrolla y comercializa Helge, que detecta la hemólisis en tubos de vacío y muestras de gases sanguíneos. Atiende a servicios de urgencias de la Unión Europea y Estados Unidos.
Bio Vitos Pharma AB (publ) Fundamentals Summary
| BIOVIT fundamental statistics | |
|---|---|
| Market cap | kr69.39m |
| Earnings (TTM) | -kr12.87m |
| Revenue (TTM) | kr3.00m |
23.2x
P/S Ratio-5.4x
P/E RatioIs BIOVIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOVIT income statement (TTM) | |
|---|---|
| Revenue | kr3.00m |
| Cost of Revenue | kr1.01m |
| Gross Profit | kr1.98m |
| Other Expenses | kr14.85m |
| Earnings | -kr12.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.044 |
| Gross Margin | 66.21% |
| Net Profit Margin | -429.54% |
| Debt/Equity Ratio | 0% |
How did BIOVIT perform over the long term?
See historical performance and comparison